163 related articles for article (PubMed ID: 33384219)
1. Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin.
Kobayashi H; Okuma T; Okajima K; Ishibashi Y; Zhang L; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Goto T; Tanaka S
J Orthop Sci; 2022 Jan; 27(1):222-228. PubMed ID: 33384219
[TBL] [Abstract][Full Text] [Related]
2. Prognostic nutrition index as a predictive factor for overall survival in trabectedin-treated advanced soft tissue sarcoma.
Sabe H; Takenaka S; Kakunaga S; Tamiya H; Wakamatsu T; Nakai S; Takami H; Yamada Y; Okada S
J Orthop Sci; 2024 Mar; ():. PubMed ID: 38467532
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
[TBL] [Abstract][Full Text] [Related]
4. Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.
Imai T; Kojima Y; Shimoi T; Aiba H; Okuma HS; Saito A; Kita S; Yamamoto K; Maejima A; Nishikawa T; Sudo K; Noguchi E; Yoshida A; Matsui Y; Iwata S; Kobayashi E; Kawai A; Udagawa R; Fujiwara Y; Yonemori K
Anticancer Res; 2024 May; 44(5):2125-2132. PubMed ID: 38677749
[TBL] [Abstract][Full Text] [Related]
5. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
[TBL] [Abstract][Full Text] [Related]
6. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Jiang C; Zhang S; Qiao K; Xiu Y; Yu X; Huang Y
Clin Breast Cancer; 2022 Jul; 22(5):424-438. PubMed ID: 35428593
[TBL] [Abstract][Full Text] [Related]
7. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Miyagawa Y; Araki K; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Nishimukai A; Kira A; Imamura M; Takatsuka Y; Miyoshi Y
Clin Breast Cancer; 2018 Oct; 18(5):400-409. PubMed ID: 29605174
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
Oba T; Maeno K; Ono M; Ito T; Kanai T; Ito KI
Anticancer Res; 2021 Jan; 41(1):445-452. PubMed ID: 33419842
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era.
Li Q; Yu L; Yang P; Hu Q
Cancer Manag Res; 2021; 13():6799-6810. PubMed ID: 34512020
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
Takamizawa S; Shimoi T; Satomi-Tsushita N; Yazaki S; Okuya T; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Yonemori K
BMC Cancer; 2022 Jan; 22(1):64. PubMed ID: 35027011
[TBL] [Abstract][Full Text] [Related]
11. Combining the systemic inflammation response index and prognostic nutritional index to predict the prognosis of locally advanced elderly esophageal squamous cell carcinoma patients undergoing definitive radiotherapy.
Yan K; Wei W; Shen W; Du X; Zhu S; Zhao H; Wang X; Yang J; Zhang X; Deng W
J Gastrointest Oncol; 2022 Feb; 13(1):13-25. PubMed ID: 35284132
[TBL] [Abstract][Full Text] [Related]
12. Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
Shimada E; Endo M; Matsumoto Y; Tsuchihashi K; Ito M; Kusaba H; Nabeshima A; Nawata T; Maekawa A; Matsunobu T; Setsu N; Fujiwara T; Iida K; Nakagawa M; Hirose T; Kanahori M; Oyama R; Isobe T; Ariyama H; Kohashi K; Yamamoto H; Oda Y; Iwamoto Y; Akashi K; Baba E; Nakashima Y
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768491
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
Kobayashi H; Okuma T; Oka H; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Sato K; Abe S; Kawano H; Goto T; Tanaka S
Int J Clin Oncol; 2018 Apr; 23(2):368-374. PubMed ID: 29086877
[TBL] [Abstract][Full Text] [Related]
14. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer.
Pacheco-Barcia V; Mondéjar Solís R; France T; Asselah J; Donnay O; Zogopoulos G; Bouganim N; Guo K; Rogado J; Martin E; Alcindor T; Colomer R
Pancreatology; 2020 Mar; 20(2):254-264. PubMed ID: 31866391
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
[TBL] [Abstract][Full Text] [Related]
16. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
17. Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin.
Fausti V; De Vita A; Vanni S; Ghini V; Gurrieri L; Riva N; Casadei R; Maraldi M; Ercolani G; Cavaliere D; Pacilio CA; Pieri F; Foca F; Bongiovanni A; Ranallo N; Calpona S; Frassineti GL; Ibrahim T; Mercatali L
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831421
[TBL] [Abstract][Full Text] [Related]
18. Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.
Tsuchihashi K; Kusaba H; Yoshihiro T; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Imajima T; Shinohara Y; Ito M; Yamaga S; Tanoue K; Arimizu K; Ohmura H; Hanamura F; Yamaguchi K; Isobe T; Ariyama H; Nakashima Y; Akashi K; Baba E
Sci Rep; 2020 Dec; 10(1):20896. PubMed ID: 33262403
[TBL] [Abstract][Full Text] [Related]
19. Nomogram based on pre-treatment inflammatory biomarkers predicting survival in patients with head and neck soft tissue sarcoma.
Chen L; Zeng H; Du Z; Zhao Y; Ma X
Cancer Biomark; 2020; 29(1):151-161. PubMed ID: 32623392
[TBL] [Abstract][Full Text] [Related]
20. The Predictive Role of Systemic Inflammation Response Index (SIRI) in the Prognosis of Stroke Patients.
Zhang Y; Xing Z; Zhou K; Jiang S
Clin Interv Aging; 2021; 16():1997-2007. PubMed ID: 34880606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
